Lactobacillus crispatus FMTA1145 C with bacteriostatic effect and application thereof

Abstract

The invention relates to the technical field of microorganisms, and provides lactobacillus crispatus FMTA1145 C with a bacteriostatic effect and application of the lactobacillus crispatus FMTA1145 C. The lactobacillus crispatus FMTA1145 C is preserved in the China General Microbiological Culture Collection Center (CGMCC) on April 22, 2025, the address of the lactobacillus crispatus FMTA1145 C is No.3, No.1 yard, Beichen West Road, Chaoyang District, Beijing, and the preservation number of the lactobacillus crispatus FMTA1145 C is CGMCC NO.34293. The lactobacillus crispatus FMTA1145 C has the advantages that the lactobacillus crispatus FMTA1145 C has the antibacterial effect, and the lactobacillus crispatus FMTA1145 C has been preserved in the China General Microbiological Culture Collection Center (CGMCC) on April 22, 2025; according to the technical scheme, the problem that the existing lactobacillus crispatus has a poor treatment effect on female vaginal diseases in the prior art is solved.

Description

Technical Field

[0001] The present invention relates to the technical field of microorganisms, and in particular to a Lactobacillus crispatus FMTA1145C with antibacterial effect and an application thereof. Background Art

[0002] The healthy female vagina is a complex and dynamic microbial ecosystem. The vaginal microbiome exists in a symbiotic relationship with the host. Fungi, particularly Candida species, exist as commensals in the vaginal mucus layer, where they, along with other bacteria, constitute a complex vaginal microbiome. Menstruation, pregnancy, sexual activity, uncontrolled antibiotic use, and vaginal douching can disrupt the vaginal microbiome. Disruption of the vaginal microbiome can lead to overgrowth of pathogens, resulting in complicated vaginal infections such as aerobic vaginitis (AV), bacterial vaginosis (BV), and vulvovaginal candidiasis (VVC), as well as serious gynecological problems such as miscarriage, premature birth, and infertility. One of the most prominent features of vaginal dysbiosis is changes in vaginal pH. It has been reported that patients with BV and VVC have significantly elevated vaginal pH due to decreased lactate concentrations compared to healthy women. Lactate is crucial for maintaining vaginal homeostasis and preventing pathogen growth.

[0003] Lactic acid bacteria are common microorganisms in the vagina of healthy women. Lactic acid bacteria include many probiotics such as Lactobacillus, Bifidobacterium and Enterococcus. Most lactic acid bacteria are generally recognized as safe (GRAS), and many of them have the characteristics of probiotics, such as strong acid resistance, bile salt resistance, salt resistance, and gastrointestinal fluid resistance. They have been widely used to prevent vaginal inflammation and restore healthy vaginal microecology. They are one of the alternatives to conventional antibacterial drugs for the treatment of vaginal pathogens. In the vaginal microbiome of most healthy women of childbearing age, 70% are lactobacilli, including Lactobacillus crispatus (Lactobacillus crispatus), Lactobacillus gasseri (Lactobacillus gasseri), Lactobacillus rhamnosus (Lactobacillus rhamnosus), Lactobacillus iners (Lactobacillus iners), Lactobacillus acidophilus (Lactobacillus acidophilus), Lactobacillus jensenii These vaginal lactobacilli can bind to host epithelial cell receptors, inhibiting the attachment of various reproductive tract pathogens, including Group B Streptococcus, Staphylococcus aureus, Gardnerella vaginalis, Pseudomonas aeruginosa, and Klebsiella pneumoniae, to epithelial cells. Furthermore, lactobacillus fermentation broth has anti-biofilm, antioxidant, pathogen-suppressing, and immunomodulatory effects.

[0004] Conventional treatments for vaginal diseases primarily involve oral or topical clindamycin and metronidazole or tinidazole. However, due to the formation of biofilms by pathogenic bacteria and the development of antibiotic resistance, treatment outcomes are poor and recurrence rates are high. In recent years, a treatment regimen combining therapeutic drugs with vaginal probiotics has been promoted. This involves using drugs to inhibit or kill pathogenic bacteria, followed by topical administration of probiotics such as Lactobacillus to exogenously supplement the vagina with probiotics, helping to restore the vagina to a normal flora dominated by Lactobacillus. Therefore, Lactobacillus has a potential beneficial effect in inhibiting the proliferation of pathogenic microorganisms, regulating the dynamic balance between vaginal microbiota, maintaining the vaginal microecology, and protecting the health of the female reproductive tract. This necessitates the development of new drugs for the treatment of vaginal infections and alternatives to traditional antibacterial treatments. Summary of the Invention

[0005] The present invention provides a Lactobacillus crispatus FMTA1145C with antibacterial effect and application thereof, which solves the problem in the related art that the existing Lactobacillus crispatus has poor therapeutic effect on female vaginal diseases.

[0006] The technical solutions of the present invention are as follows: The present invention provides a Lactobacillus crispatus FMTA1145C with antibacterial effect, wherein the Lactobacillus crispatus ( Lactobacillus crispatus ) FMTA1145C was deposited on April 22, 2025 at the General Microbiology Center of China Culture Collection Administration, located at No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing, with the deposit number CGMCCNO.34293.

[0007] As a further technical solution, the gene sequence of the Lactobacillus crispatus FMTA1145C is shown in SEQ ID No: 1, which is as follows:

[0008] The invention also provides a fermentation liquid prepared from the Lactobacillus crispatus FMTA1145C.

[0009] The present invention also provides a microbial agent, the active ingredient of which includes the Lactobacillus crispatus FMTA1145C.

[0010] As a further technical solution, the microbial agent further includes a pharmaceutically acceptable excipient or carrier.

[0011] The present invention also provides a medicine, which comprises the Lactobacillus crispatus FMTA1145C or the fermentation liquid or the microbial agent.

[0012] As a further technical solution, the dosage form of the drug includes one of lotion, gel, ointment, powder, granule, capsule and tablet.

[0013] The present invention also provides a sanitary product, wherein the active ingredient of the sanitary product contains the Lactobacillus crispatus FMTA1145C or the fermentation liquid.

[0014] The present invention also proposes the use of the Lactobacillus crispatus FMTA1145C, the fermentation broth, the microbial agent, the medicine, or the sanitary product in preventing and / or inhibiting vaginal pathogens.

[0015] As a further technical solution, the vaginal pathogens include one or more of Escherichia coli, Staphylococcus aureus, Candida albicans, Gardnerella vaginalis, and Neisseria gonorrhoeae.

[0016] The working principle and beneficial effects of the present invention are: 1. The present invention provides a strain of Lactobacillus crispatus FMTA1145C, which has good inhibitory ability against pathogens such as Escherichia coli, Staphylococcus aureus, Candida albicans, Gardnerella vaginalis and Neisseria gonorrhoeae in the vagina, and can prevent and / or treat female vaginal diseases caused by pathogens.

[0017] 2. The Lactobacillus crispatus FMTA1145C of the present invention has excellent lactic acid production, particularly D-lactic acid, creating favorable conditions for maintaining a weakly acidic pH in the vagina of healthy women and inhibiting the colonization, growth, and reproduction of pathogenic bacteria. Lactobacillus crispatus FMTA1145C also produces hydrogen peroxide, which promotes vaginal self-cleaning and helps maintain the vaginal microbiome.

[0018] 3. The content of γ-aminobutyric acid produced by the Lactobacillus crispatus FMTA1145C of the present invention is as high as 4.59 mg / mL. γ-aminobutyric acid is the main inhibitory neurotransmitter in mammals, with many important physiological functions such as calming the nerves and lowering blood pressure. It can also affect follicular development and regulate the occurrence of various reproductive diseases through specific signal transduction pathways.

[0019] 4. The Lactobacillus crispatus FMTA1145C of the present invention has no hemolytic activity and will not cause hemolytic hazards.

[0020] 5. The Lactobacillus crispatus FMTA1145C of the present invention is sensitive to antibiotics such as ampicillin, chloramphenicol, ceftriaxone, cefotaxime, erythromycin, penicillin, tetracycline, and vancomycin. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] The present invention will be further described in detail below with reference to the accompanying drawings and specific embodiments.

[0022] Figure 1 The colony morphology of Lactobacillus crispatus FMTA1145C in Example 1 of the present invention is shown; Figure 2 This is a Gram staining microscopic photograph of Lactobacillus crispatus FMTA1145C of Example 1 of the present invention; Figure 3 This is a plate image of an experiment showing that Lactobacillus crispatus FMTA1145C of Example 1 of the present invention inhibits common pathogens in the vagina; Figure 4 This is a plate image of a hemolysis test of Lactobacillus crispatus FMTA1145C according to Example 1 of the present invention; Figure 5 This is a plate diagram of an antibiotic sensitivity evaluation experiment of Lactobacillus crispatus FMTA1145C according to Example 1 of the present invention; In the figure, AMP is ampicillin, C is chloramphenicol, CRO is ceftriaxone, CTX is cefotaxime, E is erythromycin, P is penicillin, TE is tetracycline, and VA is vancomycin. DETAILED DESCRIPTION

[0023] The following will be combined with the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the embodiments described are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without making any creative efforts are within the scope of protection of the present invention.

[0024] Example 1 1. Isolation of Lactobacillus crispatus FMTA1145C Disposable sterile vaginal swabs were used to collect secretion samples from healthy women. The samples were dissolved in 1 mL of phosphate-buffered saline (PBS) for 10 minutes with constant shaking to obtain a stock sample solution. One mL of the stock sample solution was serially diluted with 9 mL of PBS and plated onto MRS solid medium (purchased from Qingdao Haibo Biotechnology Co., Ltd., Catalog No. HB0384-5). The solution was then anaerobically incubated at 37°C for 72 hours. Plates with an appropriate number of colonies were selected, and individual colonies of varying size, color, and appearance were isolated by streaking on MRS solid medium to obtain purified colonies. Purified colonies of varying morphology were transferred to 20 mL of MRS liquid medium (purchased from Qingdao Haibo Biotechnology Co., Ltd., Catalog No. HB0384-1) and incubated anaerobically at 37°C for 48 hours. The bacterial solution was then mixed with 30% glycerol at a 1:1 volume ratio and stored at -80°C until ready for use.

[0025] 2. Screening and identification of Lactobacillus crispatus FMTA1145C The isolated strains were first morphologically identified to screen out round, white colonies, Gram-positive, rod-shaped strains. Antibacterial experiments were then conducted against Escherichia coli ATCC25922, Staphylococcus aureus ATCC25923, Candida albicans ATCC10231, Gardnerella vaginalis BNCC337545, and Neisseria gonorrhoeae BNCC263826. A strain with good inhibitory effects on Escherichia coli, Staphylococcus aureus, Candida albicans, Gardnerella vaginalis, and Neisseria gonorrhoeae was screened. Finally, 16S rRNA molecular biological identification was performed and the strain was named Lactobacillus crispatus FMTA1145C. The specific procedures are as follows: 2.1 Morphological identification The screened Lactobacillus crispatus FMTA1145C was plated and cultured on MRS solid medium. The colony morphology of the cultured Lactobacillus crispatus FMTA1145C was as follows: Figure 1 As shown, 5 μL of bacterial solution was evenly spread on a glass slide, and Gram staining was performed according to the Gram staining kit (Adamas life), and the bacterial morphology was observed under an optical microscope. The Gram staining microscopy of Lactobacillus crispatus FMTA1145C is shown in the figure below. Figure 2 shown.

[0026] from Figure 1 It can be seen that the colony of Lactobacillus crispatus FMTA1145C is small, white, round, full in the middle and diffuse around.

[0027] from Figure 2 It can be seen that Lactobacillus crispatus FMTA1145C is Gram-positive and rod-shaped.

[0028] 2.2 Ability to inhibit common vaginal pathogens The screened strains were activated twice using MRS liquid medium, and then transferred to 50 mL of MRS liquid medium at a 1% inoculum volume. The culture was anaerobically cultured at 37 °C for 48 h, and the bacterial concentration was adjusted to 1 × 10 8 CFU / mL. Escherichia coli, Staphylococcus aureus, Candida albicans, Gardnerella vaginalis, and Neisseria gonorrhoeae were activated in Columbia liquid medium (purchased from Qingdao Haibo Biotechnology Co., Ltd., Catalog No. HB8511) and cultured at 37°C, 200 rpm, and shaken for 18 h. The concentration of the five pathogenic bacteria was adjusted to 1×10 6 CFU / mL. Take 200μL of pathogenic bacteria liquid and spread it on the solid plate. Use tweezers to take a four-well Oxford cup and place it on the MRS plate. Take 100μL of lactic acid bacteria liquid and add it to the Oxford cup hole, culture it at 37℃ for 24h, and measure the diameter of the inhibition zone (mm) with a vernier caliper. Test 3 parallel experiments in each group, and use fresh MRS liquid culture medium as a blank control. The plate image of the experiment of Lactobacillus crispatus FMTA1145C inhibiting vaginal pathogens is shown below. Figure 3 The results of the inhibition zone diameters are shown in Table 1.

[0029] Table 1 The ability of strains to inhibit common vaginal pathogens

[0030] pass Figure 3 As shown in Table 1, FMTA1145C exhibited strong inhibitory activity against Escherichia coli, Staphylococcus aureus, Candida albicans, Gardnerella vaginalis, and Neisseria gonorrhoeae, with significant antibacterial effects. Therefore, FMTA1145C possesses a strong ability to inhibit common vaginal pathogens.

[0031] 2.3 16S rRNA molecular biological identification DNA was extracted from the bacterial culture of FMTA1145C strain, and its 16S rRNA fragment was amplified using universal primers: 27F (5'-AGAGTTTGATCCTGGCTCAG-3') and 1492R (5'-TACGGCTACCTTGTTACGACTT-3'). The amplified product was sent to Beijing Qingke Biotechnology Co., Ltd. for sequencing. The sequence is shown in SEQ ID No: 1. The sequencing results were compared with the NCBI database, and the results showed that the strain was Lactobacillus crispatus. The strain was named Lactobacillus crispatus FMTA1145C.

[0032] 3. Functional activity assay of Lactobacillus crispatus FMTA1145C 3.1 Determination of lactic acid content Lactobacillus crispatus FMTA1145C was activated twice and then transferred to MRS liquid medium at a 1% inoculum size. The culture was incubated under anaerobes at 37°C for 48 hours. 1 mL of the culture medium was aspirated and centrifuged at 5000 rpm for 5 minutes. The supernatant was aspirated. The supernatant was diluted 20-fold with PBS, and the L-lactic acid (L-LD) content was determined using a kit (Nanjing Jiancheng Bioengineering Research Institute Co., Ltd.). The supernatant was diluted 500- or 1000-fold with PBS, and the D-lactic acid content was determined using a D-lactic acid assay kit (Nanjing Jiancheng Bioengineering Research Institute Co., Ltd.). The results are recorded in Table 2.

[0033] 3.2 Determination of hydrogen peroxide content After two activation cycles, Lactobacillus crispatus FMTA1145C was transferred to 50 mL of MRS liquid medium at a 1% inoculum volume and incubated anaerobically at 37°C for 48 hours. One mL of the bacterial culture was aspirated and centrifuged at 8000 rpm for 10 minutes. 500 μL of the supernatant was collected as a sample. Hydrogen peroxide content was measured using a hydrogen peroxide assay kit (Nanjing Jiancheng Bioengineering Research Institute Co., Ltd.). The results are recorded in Table 2.

[0034] 3.3 Determination of γ-aminobutyric acid content After two activation cycles, Lactobacillus crispatus FMTA1145C was transferred to 50 mL of MRS liquid medium at a 1% inoculum and incubated anaerobically at 37°C for 48 hours. One mL of the bacterial culture was aspirated and centrifuged at 8000 rpm for 10 minutes. The supernatant was collected and the γ-aminobutyric acid (GABA) content was determined. 0.1 mL of the supernatant was added to 0.9 mL of the extract, and the mixture was mixed by vortexing. The culture was then incubated at 95°C for 2 hours, with five vortexes. GABA content was determined using a GABA assay kit (Beijing Box Biotechnology Co., Ltd.). The results are reported in Table 2.

[0035] 3.4 Determination of the ability to inhibit Candida albicans biofilm formation After Lactobacillus crispatus FMTA1145C was transferred and activated twice, it was transferred to 50 mL of MRS liquid culture medium at a 1% inoculation volume and cultured anaerobically at 37°C for 48 hours. 1 mL of bacterial solution was aspirated, centrifuged at 8000 rpm for 10 minutes, and the supernatant was collected. 100 μL of Lactobacillus crispatus fermentation supernatant was added to the 96-well plate in sequence. MRS culture medium was used instead of Lactobacillus crispatus fermentation supernatant as a negative control. MRS culture medium containing 10 μL of chlorhexidine acetate (mass fraction of 0.1%) was used instead of Lactobacillus crispatus fermentation supernatant as a positive control. After Candida albicans was activated twice, the bacterial solution concentration was adjusted to 10 with sterile PBS buffer. 8CFU / mL, 100 μL of bacterial solution was added to each well and incubated at 37°C for 24 h. Then, the bacterial solution was removed from the wells, and each well was washed twice with 200 μL of PBS and dried. Then, 200 μL of crystal violet (0.1%) was added for staining for 15 min, and the wells were washed three times with 300 μL of PBS. After drying, 200 μL of anhydrous ethanol was added for decolorization for 15 min, and the OD values were measured at a wavelength of 570 nm. The results are recorded in Table 2.

[0036] Inhibition rate of pathogenic bacteria biofilm = (OD1-OD2) / OD1; OD1 is the OD value of the negative control, and OD2 is the OD value of the sample.

[0037] Table 2 Results of functional activity assay of Lactobacillus crispatus FMTA1145C

[0038] Table 2 shows that the D-lactic acid and L-lactic acid contents in the fermentation supernatant of Lactobacillus crispatus FMTA1145C were 187.87 mmol / L and 59.27 mmol / L, respectively. Lactic acid in the vagina has two sources. The first is L-lactic acid production by the vaginal epithelium, which accounts for 20% of total lactic acid. The second source is the vaginal microbiome, which metabolizes glycogen and produces the majority of lactic acid, primarily in the form of D-lactic acid, which accounts for 80% of total lactic acid. Lactobacillus crispatus FMTA1145C has excellent lactic acid production, particularly D-lactic acid production, which creates favorable conditions for maintaining a subacidic pH in the vagina of healthy women and inhibiting the colonization, growth, and reproduction of pathogenic bacteria.

[0039] The hydrogen peroxide content in the fermentation supernatant of Lactobacillus crispatus FMTA1145C is 53.84 mmol / L. Lactobacillus crispatus FMTA1145C can produce hydrogen peroxide, which helps with vaginal self-cleaning and maintains the vaginal microecology.

[0040] The γ-aminobutyric acid (GABA) content in the fermentation supernatant of Lactobacillus crispatus FMTA1145C is as high as 4.59 mg / mL. GABA (Gamma-aminobutyric acid) is the primary inhibitory neurotransmitter in mammals, possessing numerous important physiological functions, including calming the nerves and lowering blood pressure. In women, GABA signaling regulates the secretion of sex hormones during follicular development, thereby influencing follicular development. It can also modulate the occurrence of various reproductive diseases through specific signal transduction pathways.

[0041] During the initial adhesion stage of Candida albicans, Lactobacillus crispatus FMTA1145C had a strong inhibitory effect on Candida albicans biofilm, with an inhibition rate of up to 77.60%.

[0042] 4. Experiment on the ability of Lactobacillus crispatus FMTA1145C to interfere with the morphological transformation of Candida albicans After two activation cycles, Candida albicans was transferred to a 1% inoculum in 50 mL of YPD liquid medium and cultured overnight at 37°C with shaking at 150 rpm. The culture was centrifuged at 8000 rpm for 10 minutes, and the supernatant discarded. The cells were resuspended in 50 mL of PBS buffer and centrifuged again at 8000 rpm for 10 minutes. Then, 50 mL of fresh YPD medium (containing 2% streptomycin) was added and mixed thoroughly. One mL of the above culture was added to a 24-well plate, followed by 1 mL of fermentation supernatant from Lactobacillus crispatus FMTA1145C. A positive control used MRS instead of fermentation supernatant from Lactobacillus crispatus FMTA1145C. A negative control contained neither Lactobacillus crispatus FMTA1145C fermentation supernatant nor streptomycin. The mixture was incubated at 37°C for 21 hours. 5 μL of the mixture was then transferred to a glass slide and observed under a microscope for growth. The percentages of hyphae and yeast phases within the field of view were calculated. The results are shown in Table 3.

[0043] Table 3 Effects of Lactobacillus crispatus FMTA1145C on hyphae formation ability of Candida albicans

[0044] Table 3 shows that streptomycin stimulates the formation of Candida albicans hyphae. In the negative control group without streptomycin, the hyphae accounted for over 15%, while in the positive control group, the hyphae accounted for over 50%. Compared to the positive control, the fermentation supernatant of Lactobacillus crispatus FMTA1145C significantly inhibited the formation of Candida albicans hyphae, with the hyphae accounted for less than 30% in both cases.

[0045] 5. Lactobacillus crispatus FMTA1145C hemolysis test Lactobacillus crispatus FMTA1145C was streaked onto Columbia blood plates (purchased from Qingdao Haibo Biotechnology Co., Ltd., catalog number HB8511). Beta-hemolytic Streptococcus BNCC102660 was used as a positive control. After anaerobic incubation at 37°C for 24 hours, the colonies were observed for hemolysis. The hemolysis test plate for Lactobacillus crispatus FMTA1145C is shown in the figure below. Figure 4 shown.

[0046] from Figure 4 It can be seen that when beta-hemolytic Streptococcus BNCC102660 was used as a control and cultured on Columbia blood agar plates, a transparent hemolytic zone appeared around the colonies, indicating beta hemolysis (β hemolysis). However, when Lactobacillus crispatus FMTA1145C was inoculated on the culture medium, no transparent hemolytic zone appeared around the colonies. Therefore, it was judged that Lactobacillus crispatus FMTA1145C was not hemolytic and would not cause hemolytic hazards.

[0047] 6. Evaluation of antibiotic susceptibility of Lactobacillus crispatus FMTA1145C After Lactobacillus crispatus FMTA1145C was transferred and activated twice, it was transferred to 50 mL of MRS liquid culture medium at a 1% inoculation volume and cultured anaerobically at 37°C for 48 hours. The antibiotic sensitivity of Lactobacillus crispatus FMTA1145C was determined according to the agar diffusion paper method. After the bacterial solution was diluted 5 times (OD600 was approximately 0.1), 100 μL was spread on the MRS agar plate, and the drug-sensitive paper was attached to the surface of the agar plate. Slightly press it with tweezers, and after inverted culture in a 37°C incubator for 24 hours, the diameter of the inhibition zone was measured and recorded. The diameter of the inhibition zone is shown in Table 4, and the antibiotic sensitivity evaluation experimental plate of Lactobacillus crispatus FMTA1145C is shown in Table 4. Figure 5 As shown in the figure, AMP is ampicillin, C is chloramphenicol, CRO is ceftriaxone, CTX is cefotaxime, E is erythromycin, P is penicillin, TE is tetracycline, and VA is vancomycin.

[0048] Table 4 Inhibition zone diameters of antibiotic susceptibility test of Lactobacillus crispatus FMTA1145C

[0049] From Table 4, Figure 5 It can be seen that Lactobacillus crispatus FMTA1145C is sensitive to ampicillin (AMP), chloramphenicol (C), ceftriaxone (CRO), cefotaxime (CTX), erythromycin (E), penicillin (P), tetracycline (TE) and vancomycin (VA).

[0050] The above are only preferred embodiments of the present invention and are not intended to limit the present invention. Any modifications, equivalent replacements, improvements, etc. made within the spirit and principles of the present invention should be included in the scope of protection of the present invention.

Claims

1. A Lactobacillus crispatus FMTA1145C having an antibacterial effect, characterized in that: The Lactobacillus crispatus ( Lactobacillus crispatus ) FMTA1145C was deposited on April 22, 2025 at the General Microbiology Center of China Culture Collection Administration, located at No. 3, Yard 1, Beichen West Road, Chaoyang District, Beijing, with the deposit number CGMCCNO.34293.

2. The Lactobacillus crispatus FMTA1145C having an antibacterial effect according to claim 1, wherein The gene sequence of the Lactobacillus crispatus FMTA1145C is shown in SEQ ID No:

1.

3. A fermentation broth, characterized in that The method is prepared from the Lactobacillus crispatus FMTA1145C according to any one of claims 1 to 2.

4. A microbial agent, characterized in that: The active ingredient of the microbial agent includes the Lactobacillus crispatus FMTA1145C according to any one of claims 1 to 2.

5. A microbial agent according to claim 4, characterized in that: The microbial agent also includes pharmaceutically acceptable excipients or carriers.

6. A drug, characterized in that The medicine comprises the Lactobacillus crispatus FMTA1145C according to any one of claims 1 to 2, the fermentation broth according to claim 3, or the microbial agent according to any one of claims 4 to 5.

7. A medicine according to claim 6, characterized in that The dosage form of the medicine includes one of lotion, gel, ointment, powder, granule, capsule and tablet.

8. A sanitary product, characterized in that: The active ingredient of the sanitary product contains the Lactobacillus crispatus FMTA1145C according to any one of claims 1 to 2 or the fermentation broth according to claim 3.

9. Use of the Lactobacillus crispatus FMTA1145C according to any one of claims 1 to 2, the fermentation broth according to claim 3, the microbial agent according to any one of claims 4 to 5, the medicine according to any one of claims 6 to 7, or the sanitary product according to claim 8 in preventing and / or inhibiting vaginal pathogens.

10. The use of claim 9 in preventing and / or inhibiting vaginal pathogens, characterized in that: The vaginal pathogens include one or more of Escherichia coli, Staphylococcus aureus, Candida albicans, Gardnerella vaginalis, and Neisseria gonorrhoeae.

Images